Predictive Value of Prostate-Specific Antigen Density on Tumour Grade in Diagnosis of Prostate Cancer: A Hospital-Based Cross-Sectional Study
Main Article Content
Keywords
Gleason score, PSAD, Prostate cancer, Tumour grade
Abstract
Background: Prostate cancer is the most common urologic malignancy in men, it is witnessing a huge burden in developing countries. Prostate-specific antigen has served as a tool in diagnosis and prognostication. To improve its sensitivity, Prostate-specific antigen density is being used to discriminate between benign and malignant conditions to avoid the incidence of unnecessary biopsy. Similarly, it is important to establish the importance of Prostate-specific antigen density in prognostication to help in treatment stratification. The aim of this study, therefore, is to assess the relationship between Prostate-specific antigen density and tumour grade using the Gleason score.
Methodology: This study was a prospective cross-sectional study carried out between 2015-2016. It involved 191 consecutive patients who were either asymptomatic or symptomatic with elevated prostate-specific antigen (PSA)/abnormal digital rectal examination findings or both. They had a Prostate volume assessment and digitally guided prostate biopsy. Prostate-specific antigen density was calculated, and histopathology reports were evaluated. Data were analysed using SPSS version 20.0. Pearson correlation coefficient and test of ANOVA were used to assess the relationship between prostate-specific- antigen and Gleason score while a scatterplot was used to determine the relationship between prostate-specific antigen and prostate volume. The level of significance was set at p< 0.05
Results: All patients in this study were Nigerians, mean age of the study population was 68.2+ 9.4 years. The median PSA for patients with prostate cancer was 76.9ng/ml and 14.5ng/ml for patients with benign disease, the difference was statistically significant (p<0.001), and median prostate volume was 84.5mls while the median PSAD was 0.25. PSAD for Gleason score 2-4,5-7,8-10 was 0.4,0.8 and1.1 respectively which was statistically significant using a test of ANOVA (p=0.001). Pearson correlation coefficient revealed a statistically significant correlation between Prostate-specific antigen and Gleason score (r= 0.375, p=0.024). Using Fisher’s exact test there was a statistically significant difference between PSAD for benign prostatic disease and carcinoma of the prostate, p<0.001.
Conclusion: The study revealed that Prostate-specific antigen density has a statistically significant predictive value for tumour grade using Gleason score, however no statistically significant correlation was observed between prostate-specific antigen and prostate volume in prostate cancer.
References
2. Epstein JI, Pizov G, Walsh PC. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993; 71:3582-3593
3. Isaac AS, Mah-e-Jabeen, Pai KR, A study of biological determinants of serum prostate specific antigen level in prostatic adenocarcinoma with normal, borderline and high serum PSA levels. Arch Med Health Sci. 2014; 2:8-11
4. Yeboah ED. The prostate gland. In Badoe EA, Archampong EQ, da-Rocha-Afodu JT. Editors. Principles and practice of surgery including pathology in the tropics, 4th ed; Accra: Ghana publishing corporation; 2009: 917-952
5. Abouassaly R, Thompson IM, Jr, Platz EA, Klein EA. Epidemiology etiology and prevention of prostate cancer. In: Wein AJ, Kavoussi LR, Partin AW, Novic AC, Peters AC, editors: Campbell-Walsh’s Urology. 10th ed, Philadelphia: Saunders; 2012. 2704-27034
6. Osegbe DN. Prostate cancer in Nigerians: facts and non facts. J Urol 1997: 157(4) 1340-1343
7. Dawan D, Rafindadi, AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Aficans. BJU Int 2000; 85:1074-1077
8. Eke N, Sapira MK. Prostate Cancer in Portharcourt, Nigeria: features and outcome. Nig J Res, 2002; 4: 34-44
9. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer 2005;55(2); 74-108
10. Badmus TA, Adesunkanmi AR, Yusuf BM, Oseni G.O, Eziyi AK. Burden of Prostate Cancer in South Western Nigeria. Urology 2010; 76(2): 412-4
11. Mcneill SA, Hargreave TB, efficacy of PSA in the detection of carcinoma of the prostate in patients presenting with acute urinary retention. J.R. Coll. Surg. Edinb; 2000; 45: 227-230
12. Partin AW, Getzenberg RH. Prostate cancer tumor markers. In: Wein AJ, Kavoussi LR, Partin AW, Novic AC, Peters AC, editors Campbell-walsh’s Urology 10th ed, Philapedlphia: Saunders 2012: 2748-2762
13. Guinan P Bush I, Ray V, Veith R, Rao R, Bhatti R. The accuracy of rectal examination in the diagnosis of prostate carcinoma. N. Engl. J. Med 1980; 28: 303 (9): 499-503
14. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987; 317 (15): 909-916
15. Epstein JI, Egevad L, Amin MB, Delehunt B, Srigley JR, Humphrey PA. Grading Committee. The 2014 International Society of Urological Pathology(ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-252
16. Basourakos SP, Tzeng M, Lewicki PJ, Patel K, Al Hussein Al Awamih B, Venkat S, et al. Tissue- Based Biomarkers for the Risk Stratification of Men with Clinically Localised Prostate Cancer. Front Oncol. 2021;11:676716
17. Benson MC et al. Prostate specific antigen density: a means of distinguishing benign hypertrophy and prostate cancer. J Urol. 1992;147:815-816
18. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we learned and where we are going. J. Urol. 1999;162:293-306
19. Jin BS, Kang HS, Kim DY, Oh HG, Kim CIL, Moon GH et al. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate specific antigen density matter. Korean J Urol. 2015;56(9):624-629
20. Ha YS, Yu J, Salmasi AH, Kwon TG, Kim WJ, Kim IY et al. Prostate specific antigen density towards a better cutoff to identify better candidates for active surveillance. Urology 2014;84:365-372
21. Gleason DF. The Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma in: Tannenbaum M 9ed). Urologic Pathology: The Prostate lea & Febiger, Philadelphia 1977;171-197
22. Okolo CA, Akinosun OM, Shittu OB, Olapade-Olaopa EO, Okeke LI, et al. correlation of serum PSA and Gleason score in Nigerian men with prostate cancer. Afr J Urol. 2008; 14 (1) 15-22
23. Ezenwa E, Tijani K, Jeje A, Ogunyimi A, Ojewola R. Prevalence of Prostate Cancer amongst Nigerian with intermediate TPSA levels: experience at Lagos University Teaching Hospital Nigeria. The Internet Journal of Urology 2012: 9:3
24. Ojewola RW, Jeje EA, Tijani KH, Ogunjimi MA, Anunobi CC. Clinico-pathological Correlation of Digital Rectal Examination Findings Amongst Nigerian Men with Prostatic Diseases: A prospective study of 236 cases. Niger J Surg. 2013; 19: 26-31
25. Ozah E, Imasogie DE. The Diagnostic Accuracy of Prostate Specific Antigen and Digital Rectal Examination in the Diagnosis of Prostate Cancer at the University of Benin Teaching Hospital. J West Afr Coll Surg 2023;13(3):91-95
26. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987; 317(15): 909-919
27. Agyei-Frempong MT, Frempong NYF, Aboah K, Boateng KA. Correlation of serum free/total prostate specific antigen ratio with histological features for differential diagnosis of prostate cancer. Journal of Medical Sciences. 2008;8:540-546
28. Udeh EI, Nnabugwu II, Ozoemena FO, Ugwumba FO, Aderibigbe ASO, Ohayi SR. Prostate specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria. World Surgical Oncology 2016; 14: 174
29. Badmus TA, Asaleye CM, Takure AO, Ibrahim MH, Arowolo OA. Benign prostate hyperplasia: average volume in southwestern Nigerians and correlations with anthropometrics. Niger Postgrad Med J. 2012;19(1):15-18
30. Obiesie AE, Nwofor AME, Oranusi CK, Mbonu OO. Correlation between Prostate Volume Measured by Ultrasound and Symptom Severity Score in Patients with Benign Prostatic Hypertrophy in Southeastern Nigeria. Niger J Clin Pract 2022;25(8):1279-1286
31. Ma’aji SM, Adamu B.Transabdominal ultrasonography assessment of prostate size and volume in Nigerians with clinical diagnosis of benign prostatic hyperplasia. Niger J Clin Pract 2013;16:404
32. Aigbe E, Irekpita E, Ogbetere FE, Alili UI. Correlation Between Prostate Volume and Prostate Specific Antigen in Nigerian Men with Symptomatic Histologically Diagnosed Benign Prostatic Hyperplasia. Niger J Clin Pract. 2022;25:1523-1528
33. Okuja M, Ameda F, Dabanja H, Bongomin F, Bugeza S. Relationship between serum prostate specific antigen and transrectal prostate sonographic findings in asymptomatic Ugandan males. Afr J Urol 2021;27: 58
34. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. 1999;53(3):581-589
35. Saidi S, Georgiev V, Stavandis S, Petrovski D, Dohcev S, Levovski L et al. Does PSAD correlate with aggressiveness of prostate cancer? Hippokratia 2009; 13(4): 232-236
36. Wang D, Yang T, Zou Y, Yang X. Analysis of the correlation between prostate specific antigen related variables and risk factors in patients with prostate carcinoma. Cancer Trans Med. 2015; 1: 77-79
37. Yusuf MN, Gupta SD, Rahman MM, Ur-Rahman M. Correlation Between PSA Density and Gleason Score In Prostate Cancer Patients. Bangladesh J. Urol. 2020;23(2):164-168
38. Sfoungaristos S, Katafigiotis I, Perimenis P. The role of PSA density to predict a pathological for low risk prostate cancer in the modified Gleason system era. CUAJ 2013;7:E722-72
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.